Trial · NCT02495103
Adverse events136
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 136
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Back pain | Musculoskeletal and connective tissue disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 0 | 3 | 0 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 1 | 4 | 1 |
| other | Cognitive disturbance | Nervous system disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 0 | 3 | 0 |
| other | Cognitive disturbance | Nervous system disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 1 | 4 | 1 |
| other | Concentration impairment | Nervous system disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 0 | 3 | 0 |
| other | Concentration impairment | Nervous system disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 1 | 4 | 2 |
| other | Constipation | Gastrointestinal disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 0 | 3 | 0 |
| other | Constipation | Gastrointestinal disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 1 | 4 | 3 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 1 | 3 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 1 | 4 | 1 |
| other | Creatinine increased | Investigations | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 2 | 3 | 5 |
| other | Creatinine increased | Investigations | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 3 | 4 | 8 |
| other | Diarrhea | Gastrointestinal disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 1 | 3 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 3 | 4 | 7 |
| other | Dizziness | Nervous system disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 0 | 3 | 0 |
| other | Dizziness | Nervous system disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 1 | 4 | 2 |
| other | Dry mouth | Gastrointestinal disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 1 | 3 | 1 |
| other | Dry mouth | Gastrointestinal disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 0 | 4 | 0 |
| other | Dysphagia | Gastrointestinal disorders | Phase I, Dose Level 1 - Metformin 250mg Daily/Vandetanib 300mg Daily | 0 | 3 | 0 |
| other | Dysphagia | Gastrointestinal disorders | Phase I, Dose Level 2 - Metformin 250mg Twice Daily/Vandetanib 300mg Daily | 1 | 4 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02495103/events?page=2